SELLAS Life Sciences Group Inc (NASDAQ: SLS) is having a strong start to the trading session this morning. However, if you’re looking for press releases or SEC filings, your not going to find any. The company hasn’t released any news. Nonetheless, there’s a good reason for today’s run. Below, we’ll talk about:
- Why SLS is making a run for the top;
- what we’re seeing from the stock; and
- what we’ll be watching for ahead.
Here’s Why SLS Is Up
As mentioned above, SELLAS Life Sciences is having a strong start to the trading session, but the company hasn’t released any news. So, what’s the deal? It seems to be the result of a presentation.
In a press release issued about a week ago, SLS announced that today, it would be presenting at the San Antonio Breast Cancer Symposium from 8:30 to 10:30 a.m. EST. During the presentation, the company will discuss further correlative data from the Phase 2b trial of nelipepimut-S (NPS, NeuVax) in combination with trastuzumab (Herceptin), as a treatment for women with triple-negative breast cancer.
In the press release, SLS said that the data will include efficacy results from an analysis of key predefined subgroups and the difference in the patterns of disease relapse between the active vursus the control arms.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. When it comes to SELLAS Life Sciences, the news was released a short while ago, but the event is taking place today, and it seems to be driving investor interest. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:36), SLS is trading at $1.95 per share after a gain of $0.09 per share or 4.84% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the iWatch Markets team will continue to keep a close eye on SLS. In particular, we’re interested in following the presentation and the continued development of the company’s breast cancer treatment. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the iWatch Markets mailing list below!